Gujarat Themis Biosyn Ltd · NSE:GUJTHEM

Gujarat Themis Biosyn — Q3 FY2025-26 Earnings Presentation

17 slides from Gujarat Themis Biosyn's earnings presentation, Feb 5, 2026

  1. Slide 1: Gujarat Themis Biosyn Limited exchange filing letter

    GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL/BSE/NSE/2025-26/47 5th February, 2026 Corporate Relationship Department Listing Department

  2. Slide 2: Investor Presentation Q3 & 9M FY2025-26

    Gujarat Themis Biosyn Limited Investor Presentation Q3 & 9M FY2025-26

  3. Slide 3: Disclaimer

    Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t

  4. Slide 4: Management Comment

    Click to edit MasterComment Management title style Commenting on the result, Dr. Sachin Patel, Director said: “The third quarter performance has been well in line with expectations, continuing on the momentum of the previous quarters. Consistency in volumes reflects a healthy demand scenario for our

  5. Slide 5: Quarterly Financial Highlights

    Click to edit Master Quarterly titleHighlights Financial style Revenue (Rs. Cr) 42.4 43.4 39.5 37.7 35.9 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 60% 47.7% 49.5% 49.1% 16 32.8% 40% 20 42.5% 50% 33.7% 14 31.8% 35% 38.8% 28.7% 40% 12 25.2% 30% 1

  6. Slide 6: Quarterly Financial Highlights

    Click to edit Master Quarterly titleHighlights Financial style Rs. Cr. Q3 FY26 Q3 FY25 YoY% Q2 FY26 Income from Operations 43.37 39.52 42.35 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 43.37 39.52 9.74% 42.35 Cost of Materials Consumed 6.62 6.55 6.92 Changes In Inventory (0.80

  7. Slide 7: Nine Months Financial Highlights

    Click to edit Nine Master Months title style Financial Highlights Rs. Cr. 9M FY26 9M FY25 YoY% Income from Operations 121.59 113.06 Other Operating Income 0.00 0.00 Total Income from Operations 121.70 113.06 7.54% Cost of Materials Consumed 20.37 18.93 Changes In Inventory (2.53) (0.65) Employee Cos

  8. Slide 8: Annual Financial Highlights

    Click to edit Master Annual Financialtitle style Highlights Revenue (Rs. Cr) 169.82 148.39 150.80 114.85 90.56 FY20-21 FY21-22 FY22-23 FY23-24 FY24-25 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 90 50.5% 49.6% 51% 46.4% 80 50% 70 45% 38.0% 39.1% 45.7% 49% 34.8% 40% 70 60 33.3% 48% 32.3% 6

  9. Slide 9: Balance Sheet Highlights – As on 30th September 2025

    Click to edit Master Balance title style– As on 30th September 2025 Sheet Highlights Rs. Cr. As on 30th As on 31st Rs. Cr. As on 30th As on 31st Mar, Total Equity & Liabilities Sep, 2025 Mar, 2025 Total Assets Sep, 2025 2025 Shareholders Funds 264.43 248.38 Non Current Assets 321.87 249.34 Share Cap

  10. Slide 10: Key Balance Sheet Ratios

    Keyedit Click to Balance Sheet Master Ratios title style RoCE(%)* RoA(%)** 35.6% 34.9% 57.9% 26.8% 52.1% 39.4% 16.2% 23.6% FY21-22 FY22-23 FY23-24 FY24-25 FY21-22 FY22-23 FY23-24 FY24-25 RoE(%)*** 42.2% 38.9% 29.4% 19.6% FY21-22 FY22-23 FY23-24 FY24-25 Company has been investing in Capex over last t

  11. Slide 11: Among India's few fermentation based Intermediate manufacturers

    Click Among to edit India’s Masterfew title style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation-based State of Art Manufacturing Facility manufacturers in pharmaceutical field  Plant in Vapi (Gujarat)  Over 200 Employees engaged  Incorporated in 1981 as j

  12. Slide 12: Product Portfolio – Strong & Niche

    Click toStrong edit Master & Niche title style Product Portfolio – Growing at a fast pace Current Product Portfolio Rifamycin  An intermediate for Rifamycin S  An intermediate for manufacturing drug Rifampicin O manufacturing drug Rifaximin (Anti biotic used for treatment of (Antibiotic used for t

  13. Slide 13: Expansion Strategy to Spur Growth

    Click to edit Master Expansion titletostyle Strategy Spur Growth Capex Research & Development Forward Integration Fermentation  Ventured into API production as  New Product Development part of forward integration  Expanding fermentation capacity  R&D Unit Commissioned, as per strategy  Addition

  14. Slide 14: State of Art Manufacturing Facilities at Vapi

    Click to editofMaster State title style Facilities at Vapi Art Manufacturing Among very few companies in India with fermentation capabilities for Intermediates Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 13

  15. Slide 15: Our Way Ahead

    Click to Ouredit Way Master Aheadtitle style  In process of identifying new products which have good domestic & export New Product Development & potential  Company strategizing to move up the value chain through forward integration into Forward Integration API – recently began commercial operation

  16. Slide 16: Hybrid Renewable Power Project

    Click to edit Renewable Hybrid Master titlePower styleProject Strategic ESG & Cost Optimization Initiative  Advancing the Company’s ESG roadmap Capacity through increased adoption of renewable Wind + Solar Hybrid energy for captive consumption, thus ~ 18.5 MW lowering carbon footprint  Hybrid wind

  17. Slide 17: Thank You

    Click to editYou Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Adfactors PR Pvt. Ltd. Mr. Pradeep Chandan Mr. Rahul Trivedi Mr. Vivek Sahu pradeep.chandan@themismedicare.com rahul.trivedi@adfactorspr.com vivek.

Gujarat Themis Biosyn — Q3 FY2025-26 Earnings Presentation on 6ix